对BRCA1/2-阳性转移性割抵抗性前列腺癌患者的治疗模式
Mehmet A Bilen1, Ibrahim Khilfeh2, Carmine Rossi3
1Emory University School of Medicine, Atlanta, GA, United States.
The oncologist
|July 31, 2024
概括
对BRCA阳性转移性割耐性前列腺癌 (mCRPC) 的治疗通常涉及雄激素剥夺疗法 (ADT) 单疗法,恩扎胺或olaparib. 患有BRCA阳性mCRPC的患者面临着不良的预后,这强调了改善治疗的必要性.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 在患有BRCA突变的患者中,转移性割抵抗性前列腺癌 (mCRPC) 呈现出积极的临床过程.
- 了解现实世界治疗动态对于这个患者子组至关重要.
研究的目的:
- 描述确诊BRCA阳性mCRPC的患者的现实世界治疗模式.
- 分析一线 (1L) 和二线 (2L) 治疗序列和结果.
主要方法:
- 利用了来自Flatiron Health-Foundation Medicine Inc.数据库 (2011-2022) 的非识别电子健康记录数据.
- 精选的BRCA阳性mCRPC患者开始1L治疗,使用先进的治疗线 (LOT) 或雄激素剥夺疗法 (ADT) 单疗法.
- 描述了1L和2L疗法的治疗序列,审查原因和时间到下一次治疗.
主要成果:
- 确定了98名BRCA阳性mCRPC治疗患者.
- 最受欢迎的1L疗法包括ADT单疗 (19%),恩扎拉胺 (14%),和奥拉巴里布 (13%).
- 从1L开始到下一次治疗的中位时间是6.2个月; 43%的1L中接受高级LOT的患者没有开始2L治疗.
结论:
- 雄激素剥夺疗法 (ADT) 单疗法,恩扎胺和奥拉巴里布是BRCA阳性mCRPC的常见1L治疗方法.
- 这些患者的预后很差,经常出现治疗失败,导致治疗切换或死亡.
- 研究结果强调迫切需要更早,更有效的治疗策略来治疗BRCA阳性mCRPC.
更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.8K
08:34Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
20.3K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K